THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO signed an agreement with Advaxis Inc. to evaluate several new immunotherapy constructs, each built on Advaxis proprietary technology.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
